Back to search

Cordyceps, Scarlet Club · 2025 · Brief Report

Medium relevance

Exploring Cordycepin as a Neuroprotective Agent in Huntington's Disease: In Vitro and In Vivo Insights.

Cordyceps militaris

Cognition & nervesEnergy & fatigue
SpeciesCordyceps, Scarlet Club
JournalPharmacology research & perspectives
Year2025

Key points

  • Huntington's disease (HD) is a challenging neurodegenerative disorder linked to Huntingtin (HTT) gene mutation, lacking an effective cure despite numerous therapeutic attempts
  • Cordyceps sinensis, recognized for its health benefits, particularly its constituent cordycepin, exhibits neuroprotective effects in various neurodegenerative diseases
  • However, the neuroprotective potential of cordycepin in HD remains insufficiently explored
  • In this study, in vitro experiments using HD cell models demonstrate that cordycepin treatment enhances cell survival, slightly diminishes mutant HTT aggregates, and improves neuronal formation
  • In vivo investigations on R6/2 HD transgenic mice reveal a modest increase in body weight and a slight amelioration in pathological aggregates following cordycepin administration, although behavioral changes are not significant
  • While the underlying mechanisms remain unexplored, the findings suggest cordycepin's promise as a supplementary therapeutic for HD, providing neuroprotective effects and reducing mutant protein aggregates

Metadata-grounded summary

Citation abstract

Huntington's disease (HD) is a challenging neurodegenerative disorder linked to Huntingtin (HTT) gene mutation, lacking an effective cure despite numerous therapeutic attempts. Cordyceps sinensis, recognized for its health benefits, particularly its constituent cordycepin, exhibits neuroprotective effects in various neurodegenerative diseases. However, the neuroprotective potential of cordycepin in HD remains insufficiently explored. In this study, in vitro experiments using HD cell models demonstrate that cordycepin treatment enhances cell survival, slightly diminishes mutant HTT aggregates, and improves neuronal formation. In vivo investigations on R6/2 HD transgenic mice reveal a modest increase in body weight and a slight amelioration in pathological aggregates following cordycepin administration, although behavioral changes are not significant. While the underlying mechanisms remain unexplored, the findings suggest cordycepin's promise as a supplementary therapeutic for HD, providing neuroprotective effects and reducing mutant protein aggregates.

Citation

Tung CW, Chan SC, Cheng PH, Chen YC, Wu PM, Lin WC, et al. (2025). Exploring Cordycepin as a Neuroprotective Agent in Huntington's Disease: In Vitro and In Vivo Insights. Pharmacology research & perspectives https://doi.org/10.1002/prp2.70091 PMID: 40202221

Open citation